Predict your next investment

HEALTHCARE | Drug Development
rxkinetix.com

See what CB Insights has to offer

Founded Year

1996

Stage

Acquired | Acquired

Total Raised

$11.86M

Valuation

$0000 

About RxKinetix

RxKinetix is a product-focused specialty pharmaceutical company engaged in the research and development of novel pharmaceutical formulations. The company's lead product is RK-0202, an oral rinse for the prevention and treatment of oral mucositis, a painful and debilitating side-effect of cancer therapy. RxKinetix also has an emerging anti-viral formulation for the prevention and treatment of herpes simplex outbreaks, as well as programs involving vaccine, therapeutic antibody, and growth factor formulations.

RxKinetix Headquarter Location

3122 Sterling Circle Suite 200

Boulder, Colorado, 80301,

United States

303-926-1900

Latest RxKinetix News

Awarded Grant by the National Institute Of Allergy and Infectious Diseases

Jul 11, 2017

Grant to Fund Early Research of an Anthrax Vaccine Using Company's Proprietary Technology Sep 24, 2002, 01:00 ET from RxKinetix, Inc. LOUISVILLE, Colo., Sept. 24 /PRNewswire/ -- RxKinetix, Inc. today announced that it has been awarded a $224,500 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund early stage development of a novel adjuvant/delivery system for anthrax vaccine. The program will use the company's proprietary ProJuvant(TM) technology, in collaboration with research conducted at the Medical College of Ohio, in an effort to create an improved vaccine against the infectious bacterium, Bacillus anthracis. This project builds on the successful use of ProJuvant in proof-of-concept studies with tetanus that have demonstrated superior vaccine potency with reduced frequency of administration using the approaches that will be taken with anthrax. ProJuvant is a polymer-based matrix that incorporates an immune response enhancer. The resulting adjuvant, which is liquid at ambient or cool temperatures, becomes a pliable gel at body temperature for improved immune system exposure to the antigen. It can be dosed through systemic injections or non-invasive, intranasal administration. These formulations also may allow many conventional vaccines to be administered in single-doses without the common immunization/boost schedule. Preparation and production of the novel vaccine formulation will be carried out at RxKinetix's Colorado location, while testing of the vaccine will be performed under contract by an independent laboratory. "This grant from the NIAID further validates the innovative work we're doing with the delivery of vaccine candidates," said RxKinetix President and Chief Executive Officer, John E. Lucas. "The project is an extension of our ongoing vaccine research. It will help us to seek a tool against anthrax and to develop other company projects in which the goal is to improve immune responses." This Phase I grant is expected to fund a year of research. Should the program prove successful, the company will apply for a larger Phase II grant. RxKinetix, Inc. is a product-focused specialty pharmaceutical company engaged in the research and development of novel pharmaceutical formulations. The company's lead product is RK-0202, an oral rinse for the prevention and treatment of oral mucositis, a painful and debilitating side-effect of cancer therapy. RxKinetix also has an emerging anti-viral formulation for the prevention and treatment of herpes simplex outbreaks, as well as programs involving vaccine, therapeutic antibody, and growth factor formulations. More information regarding RxKinetix is available at www.rxkinetix.com . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X31250383 SOURCE RxKinetix, Inc. LOUISVILLE, Colo., Sept. 24 /PRNewswire/ -- RxKinetix, Inc. today announced that it has been awarded a $224,500 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund early stage development of a novel adjuvant/delivery system for anthrax vaccine. The program will use the company's proprietary ProJuvant(TM) technology, in collaboration with research conducted at the Medical College of Ohio, in an effort to create an improved vaccine against the infectious bacterium, Bacillus anthracis. This project builds on the successful use of ProJuvant in proof-of-concept studies with tetanus that have demonstrated superior vaccine potency with reduced frequency of administration using the approaches that will be taken with anthrax. ProJuvant is a polymer-based matrix that incorporates an immune response enhancer. The resulting adjuvant, which is liquid at ambient or cool temperatures, becomes a pliable gel at body temperature for improved immune system exposure to the antigen. It can be dosed through systemic injections or non-invasive, intranasal administration. These formulations also may allow many conventional vaccines to be administered in single-doses without the common immunization/boost schedule. Preparation and production of the novel vaccine formulation will be carried out at RxKinetix's Colorado location, while testing of the vaccine will be performed under contract by an independent laboratory. "This grant from the NIAID further validates the innovative work we're doing with the delivery of vaccine candidates," said RxKinetix President and Chief Executive Officer, John E. Lucas. "The project is an extension of our ongoing vaccine research. It will help us to seek a tool against anthrax and to develop other company projects in which the goal is to improve immune responses." This Phase I grant is expected to fund a year of research. Should the program prove successful, the company will apply for a larger Phase II grant. RxKinetix, Inc. is a product-focused specialty pharmaceutical company engaged in the research and development of novel pharmaceutical formulations. The company's lead product is RK-0202, an oral rinse for the prevention and treatment of oral mucositis, a painful and debilitating side-effect of cancer therapy. RxKinetix also has an emerging anti-viral formulation for the prevention and treatment of herpes simplex outbreaks, as well as programs involving vaccine, therapeutic antibody, and growth factor formulations. More information regarding RxKinetix is available at www.rxkinetix.com . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X31250383 SOURCE RxKinetix, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RxKinetix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RxKinetix is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.